Status:
COMPLETED
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Lead Sponsor:
Gilead Sciences
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigatio...
Detailed Description
ADVANCE MPI 1 is a multi-national, double-blind, randomized, active-controlled, parallel group clinical trial to evaluate the safety and efficacy of regadenoson in SPECT MPI compared to that of the ap...
Eligibility Criteria
Inclusion
- Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study
Exclusion
- Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study
- Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
1231 Patients enrolled
Trial Details
Trial ID
NCT00208299
Start Date
October 1 2003
End Date
August 1 2006
Last Update
November 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple study locations (see Central Contact); CV Therapeutics, Inc.
Palo Alto, California, United States, 94304